Skip to content
OpenCapital
Get started

Halozyme Therapeutics HALO Proceeds From Sale And Maturity Of Available For Sale Securities

Proceeds From Sale And Maturity Of Available For Sale Securities at other companies

BridgeBio Pharma logo
BridgeBio PharmaBBIO
——
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
——
Spyre Therapeutics, Inc. logo
Spyre Therapeutics, Inc.SYRE
——
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
——

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities.

The official record: Halozyme Therapeutics’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities?
Halozyme Therapeutics (HALO) reported proceeds from sale and maturity of available for sale securities of $180.56M in Q4 2025.
How has Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities changed year-over-year?
Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities increased by 82.6% year-over-year, from $98.89M to $180.56M.
What is the long-term trend for Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities?
Over 4 years (2021 to 2025), Halozyme Therapeutics's proceeds from sale and maturity of available for sale securities has grown at a 30.7% compound annual growth rate (CAGR), from $247.68M to $722.25M.